Core Viewpoint - Integer (ITGR) is currently more attractive to value investors compared to Penumbra (PEN) based on various valuation metrics and earnings outlook [1][3]. Valuation Metrics - ITGR has a forward P/E ratio of 19.17, significantly lower than PEN's forward P/E of 69.63 [5]. - The PEG ratio for ITGR is 1.04, indicating a more favorable valuation relative to its expected earnings growth, while PEN's PEG ratio stands at 2.31 [5]. - ITGR's P/B ratio is 2.63, compared to PEN's P/B of 8.27, suggesting that ITGR is undervalued relative to its book value [6]. Zacks Rank and Value Grades - ITGR holds a Zacks Rank of 1 (Strong Buy), indicating a stronger improvement in earnings outlook compared to PEN, which has a Zacks Rank of 2 (Buy) [3]. - Based on the valuation metrics, ITGR has a Value grade of B, while PEN has a Value grade of D, reinforcing the view that ITGR is the better option for value investors [6].

Core Insights - The Medical Instruments industry is experiencing significant advancements due to artificial intelligence (AI) and predictive analytics, which are driving innovation in diagnostics, patient monitoring, and personalized treatment [2][4] - The global AI in healthcare market is projected to grow at a CAGR of 38.5% from 2024 to 2030, despite facing challenges such as geopolitical tensions and supply chain issues [4][8] - The industry is currently underperforming compared to the S&P 500 but has shown resilience against sector declines [17] Industry Overview - The Zacks Medical - Instruments industry is highly fragmented, involving extensive research and development across various therapeutic areas, regulated by the FDA [5] - Recent trends include the integration of AI in diagnostics, the rise of telemedicine, robotic-assisted surgeries, and advancements in 3D printing and gene editing [6][9] - The ongoing merger and acquisition trend is notable, with 305 M&A transactions in 2024 totaling over $63.1 billion, indicating a competitive landscape [10][11] Company Highlights Integer Holdings - Integer Holdings focuses on portfolio optimization and has divested its Non-Medical business to support long-term growth [20] - The consensus estimate for 2025 sales is $1.87 billion, reflecting a 7.7% increase from 2024, with EPS expected to rise by 19.4% to $6.33 [21] AngioDynamics - AngioDynamics is focusing on cancer treatment markets and has a strong product pipeline, with sales for fiscal 2026 estimated at $305 million, a 6.3% increase from fiscal 2025 [22][23] Penumbra - Penumbra is experiencing consistent revenue growth driven by strong patient outcomes and growth in its vascular and neuro businesses [24] - The consensus estimate for Penumbra's 2025 sales is $1.35 billion, indicating a 13.4% rise from 2024, with EPS expected to improve by 67.6% to $3.72 [25]

Company Overview - Integer Holdings Corporation (NYSE: ITGR) is a leading medical device contract development and manufacturing organization (CDMO) serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets [3] - The company is recognized as a strategic partner for medical device companies and OEMs, focusing on enhancing patient lives through innovative, high-quality products and solutions [3] - Integer's brands include Greatbatch Medical and Lake Region Medical [3] Upcoming Events - Integer will participate in the 2025 Truist Securities MedTech Conference on June 17, 2025, in Boston, with a fireside chat scheduled for 10:40 a.m. ET [1] - A live webcast of the presentation will be available on the Investor Relations section of the Integer website [2]

Core Viewpoint - Integer (ITGR) is currently viewed as a better value opportunity compared to SONOVA HOLDING (SONVY) based on various financial metrics and Zacks Rank evaluations [1][7]. Valuation Metrics - Integer has a forward P/E ratio of 18.77, while SONOVA HOLDING has a higher forward P/E of 25.39 [5]. - The PEG ratio for Integer is 1.02, indicating a more favorable valuation in relation to its expected earnings growth, compared to SONOVA's PEG ratio of 3.44 [5]. - Integer's P/B ratio stands at 2.58, significantly lower than SONOVA's P/B ratio of 7.47, suggesting that Integer is more undervalued relative to its book value [6]. Earnings Outlook - Integer is experiencing an improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, indicating a positive trend in earnings estimate revisions [3][7].

Summary of Integer Holdings Conference Call Company Overview - **Company**: Integer Holdings - **Industry**: Medical Technology (Med Tech) Key Points and Arguments CEO Transition - Joe Dizik, the current CEO, is transitioning to retirement, with Peyman Kales set to take over later this year [5][7] - The transition is seen as timely, with the company in a strong position, having met strategic objectives set in 2018 [7][8] Financial Performance and Guidance - Integer Holdings reported sales growth of 8% to 10% for the year, with organic growth of 6% to 8% [8] - Net income is expected to rise by 19% to 26%, and earnings per share guidance is set at 16% to 23% [8] - Q1 results showed 6% organic growth, with a reported 17% growth in the cardiovascular segment [19][20] Strategic Focus and Market Position - The company has a strong presence in growth markets, particularly in electrophysiology (EP) and pulsed field ablation (PFA) [15][16] - The pipeline of opportunities has increased by 270%, with 80% focused on growth markets [16] - Integer Holdings aims to maintain a debt leverage ratio of 2.5 to 3.5, which is considered prudent for the industry [8][17] Operational Insights - Operating income grew by 14% in Q1, indicating strong operational leverage [28] - The company expects to see improvements in gross margins and operational efficiencies, particularly in R&D [30][32] - Integer Holdings is exiting the portable medical business, which is expected to decline by $29 million year-over-year, offset by $59 million from acquisitions [26][27] Tariff and Supply Chain Management - The expected tariff impact for 2025 is estimated to be between $1 million to $5 million, due to the company's supply chain positioning [40][41] - Integer Holdings has a global manufacturing footprint, which mitigates tariff risks [46][47] Growth Areas - The cardiovascular business has reached $1 billion and is growing double digits, driven by acquisitions and market expansion [55] - Emerging markets such as neuromodulation and cardiac rhythm management are expected to drive future growth, with a projected growth rate of 15% to 20% [66][67] Portfolio Management - Integer Holdings has divested non-core assets to focus on high-potential markets, particularly in cardiovascular and neuromodulation [68][70] - The company emphasizes the importance of cash generation from established segments to fund growth in faster-growing areas [70][72] Additional Important Insights - The leadership transition is expected to be smooth, with Peyman Kales being well-prepared to take over [11][15] - The company maintains strong relationships with customers, which aids in navigating pricing pressures and cost management [52][54] - Integer Holdings is committed to a long-term growth strategy, focusing on innovation and market leadership in targeted segments [17][60]

Core Insights - Integer (ITGR) is currently rated as a Strong Buy with a Zacks Rank of 1, while SONOVA HOLDING (SONVY) has a Zacks Rank of 4, indicating a Sell recommendation [3] - ITGR is showing an improving earnings outlook, which is a significant factor in its favorable ranking [7] Valuation Metrics - ITGR has a forward P/E ratio of 18.61, compared to SONVY's forward P/E of 23.74, suggesting that ITGR may be undervalued relative to SONVY [5] - The PEG ratio for ITGR is 1.01, while SONVY's PEG ratio is significantly higher at 3.22, indicating that ITGR has a better growth-to-price ratio [5] - ITGR's P/B ratio stands at 2.53, whereas SONVY's P/B ratio is 6.99, further supporting the notion that ITGR is a more attractive value option [6] - Based on these valuation metrics, ITGR holds a Value grade of B, while SONVY has a Value grade of D [6]

Shares of Integer (ITGR) have gained 3.2% over the past four weeks to close the last trading session at $116.55, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $150.38 indicates a potential upside of 29%.The mean estimate comprises eight short-term price targets with a standard deviation of $6.95. While the lowest estimate of $140 indicates a 20.1% increase from the current pri ...

Core Viewpoint - Integer Holdings Corporation is actively participating in the 2025 Bank of America Securities Health Care Conference, indicating its engagement with the healthcare investment community and commitment to showcasing its innovations in medical devices [1]. Company Overview - Integer Holdings Corporation (NYSE: ITGR) is a leading medical device contract development and manufacturing organization (CDMO) globally, focusing on cardiac rhythm management, neuromodulation, and cardio and vascular markets [3]. - The company serves as a strategic partner to medical device companies and OEMs, aiming to enhance patient lives through innovative and high-quality products [3]. - Integer's notable brands include Greatbatch Medical and Lake Region Medical, reflecting its strong market presence [3]. Event Details - The 2025 Bank of America Securities Health Care Conference will take place from May 13-15, 2025, in Las Vegas, where Integer's executive leadership will participate in a fireside chat on May 14 at 10:00 a.m. PT [1]. - A live webcast of the presentation will be available on the Investor Relations section of the Integer website, allowing broader access to stakeholders [2].

Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.31 in the first quarter of 2025, which improved 14.9% year over year. The figure topped the Zacks Consensus Estimate by 3.2%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP loss per share for the quarter was 66 cents, against EPS of 59 cents in the p ...

Integer (ITGR) Q1 2025 Earnings Call April 25, 2025 12:52 AM ET Company Participants Sanjiv Arora - SVP, Strategy, Business Development and IRJoseph Dziedzic - President & CEOPayman Khales - COODiron Smith - Executive VP & CFORichard Newitter - Managing DirectorNathan Treybeck - Equity Research Vice PresidentAndrew Cooper - VP - Equity ResearchJoanne Wuensch. - Managing DirectorSuraj Kalia - Managing Director Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystCraig Bijou - ...